hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
1 element (tin) has 10 stable isotopes 5 elements have 7 stable isotopes apiece 7 elements have 6 stable isotopes apiece 11 elements have 5 stable isotopes apiece 9 elements have 4 stable isotopes apiece 5 elements have 3 stable isotopes apiece 16 elements have 2 stable isotopes apiece 26 elements have 1 single stable isotope. These last 26 are thus called monoisotopic elements. The mean number of stable isotopes for elements which have at least one stable isotope is 251/80 = 3.1375.
An insulin analogue (also called an insulin analog) is a type of medical insulin that has been modified to alter its pharmacokinetic properties while maintaining the same biological function as human insulin. These modifications are achieved through genetic engineering, which allows for changes in the amino acid sequence of insulin to optimize its absorption, distribution, metabolism, and excretion (ADME) characteristics. All insulin analogues work by enhancing glucose uptake in tissues and reducing glucose production by the liver. They are prescribed for conditions such as type 1 diabetes, type 2 diabetes, gestational diabetes, and diabetes-related complications such as diabetic ketoacidosis. Additionally, insulin is sometimes administered alongside glucose to treat elevated blood potassium levels (hyperkalemia). Insulin analogues are classified based on their duration of action. Short-acting (bolus) insulin analogues, such as insulin lispro, insulin aspart, and insulin glulisine, have been designed to be absorbed quickly, mimicking the natural insulin response after meals. Long-acting (basal) insulin analogues, including insulin glargine, insulin detemir, and insulin degludec, provide a sustained release of insulin to maintain basal blood glucose levels over an extended period. These modifications enhance the predictability of insulin therapy and reduce the risk of hypoglycemia compared to regular human insulin. Lispro, the first insulin analogue, was approved in 1996. This was followed by an influx of new analogues with differing pharmacokinetic properties.
The UNESCO International Bioethics Committee recommended a precautionary global moratorium on the creation of mirror-image organisms, and the UK Government Office for Science held an expert roundtable that recommended "prevent[ing] the development of replicating mirror organisms." Several philanthropic funders have also stated that they will not fund research with the goal of creating mirror-image organisms, including Renaissance Philanthropy. In 2026, the UN Scientific Advisory Board called for "proactive multilateral action, such as a dedicated global forum, to define clear 'red lines', strengthen safety and monitoring practices, and establish responsible policy well before mirror life becomes feasible", and Chinese and US policy research organizations issued a joint statement calling for "national and international frameworks to guard against the risks posed by mirror life, reaffirming the shared view that such organisms should never be created." Some scientists and scholars have argued that concerns about mirror-image life are theoretical and/or that bans on research and funding bans are premature. Others have argued that the immune system might be able to recognize mirror versions of a certain type of biomolecule. Some scientists have proposed developing guidelines for synthetic biological entities regardless of their chirality.
Sources: en.wikipedia.org
N1-Methyl-2-pyridone-5-carboxamide (also known as 1-methyl-6-oxopyridine-3-carboxamide or nudifloramide and abbreviated as 2PY, 2-Py or NMPC) is one of a number of metabolic products of nicotinamide adenine dinucleotide (NAD) degradation. The presence of 2PY in human blood serum can be an indication of poor kidney performance or chronic kidney disease. 2PY has been identified as a product of the metabolism of caffeine and niacin. 2PY's molecular formula is C7H8N2O2 and its molecular weight 152.153 g/mol.
== Symptoms and signs == For reasons that are not understood, many people with defective variants of the AMPD genes are asymptomatic, while others have symptoms including exercise intolerance, and/or muscle pain and cramping.
Pakistani officials attributed several of these attacks to militant groups operating from Afghan territory and warned that military action could follow if the Taliban did not act against these groups. On 11 February 2026, Pakistani Defence Minister Khawaja Asif warned that Pakistan may take action against militants in Afghanistan before the start of the Islamic month of Ramadan if the Taliban failed to deter militant activities from the territory under their control. Following further attacks in February, Pakistani officials signalled that their restraint had been exhausted, setting the stage for the airstrikes that began the conflict.
Myofascial release (MFR, self-myofascial release) is an alternative medicine therapy that proponents claim to be useful for treating skeletal muscle immobility and pain by relaxing contracted muscles, improving blood and lymphatic circulation, and stimulating the stretch reflex in muscles. Fascia is a thin, tough, elastic type of connective tissue that wraps most structures within the human body, including muscle. Fascia supports and protects these structures. Osteopathic practitioners hold that this soft tissue can become restricted due to psychogenic disease, overuse, trauma, infectious agents, or inactivity, often resulting in pain, muscle tension, and corresponding diminished blood flow.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.